The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib
Open accessAbstract
BACKGROUND: Observational studies have shown reduced risk of Alzheimer dementia in users of nonsteroidal anti-inflammatory drugs. OBJECTIVE: To evaluate the effects of naproxen sodium and celecoxib on cognitive function in older adults. DESIGN: Randomized, double-masked chemoprevention trial. SETTING: Six US memory clinics. PARTICIPANTS: Men and women aged 70 years and older with a family history of Alzheimer disease; 2117 of 2528 enrolled had follow-up cognitive assessment. INTERVENTIONS: Celecoxib (200 mg twice daily), naproxen sodium (220 mg twice daily), or placebo, randomly allocated in a ratio of 1:1:1.5, respectively. MAIN OUTCOME MEASURES: Seven tests of cognitive function and a global summary score measured annually. RESULTS: Longitudinal analyses showed lower global summary scores over time for naproxen compared with placebo (- 0.05 SDs; P = .02) and lower scores on the Modified Mini-Mental State Examination over time for both treatment groups compared with placebo (- 0.33 points for celecoxib [P = .04] and - 0.36 points for naproxen [P = .02]). Restriction of analyses to measures collected from persons without dementia attenuated the treatment group differences. Analyses limited to measures obtained while participants were being issued study drugs produced results similar to the intention-to-treat analyses. CONCLUSIONS: Use of naproxen or celecoxib did not improve cognitive function. There was weak evidence for a detrimental effect of naproxen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Considering the failure of prospective studies with NSAID treatment (111), the beneficial effects of NSAIDs is presumed to be related to pre-morbid function.”
From The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease (2018) · cites this paper as [111]
In the citing paper
“long-term, large-scale population trials on nonsteroidal anti-inflammatory drugs (NSAIDs) for AD treatment have shown that ibuprofen may have a protective effect on AD,509 while other NSAIDs seemingly do not.510”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [510]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L., Hempelman, S. R., Berry, D. A., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 991
Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review
Szekely, C. A., Thorne, J. E., Zandi, P. P., Ek, M., Messias, E., Breitner, J. C. S., & Goodman, S. N. (2004) · Neuroepidemiology · doi:10.1159/000078501 · Cited by 402
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402
A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease
Scharf, S., Mander, A. G., Ugoni, A., Vajda, F. J. E., & Christophidis, N. (1999) · Neurology · doi:10.1212/wnl.53.1.197 · Cited by 385
Reines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R., Norman, B., & Baranak, C. C. (2004) · Neurology · doi:10.1212/wnl.62.1.66 · Cited by 384
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354
Self-citationReduced incidence of AD with NSAID but not H2receptor antagonists
Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K. M., Mayer, L. S., & Breitner, J. C. S. (2002) · Neurology · doi:10.1212/wnl.59.6.880 · Cited by 317
Research works printed but not linked: 2
- Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1):66-71.
- Sainati S, Ingram D, Talwalker S, Geis G. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzhei- mer's disease. Presented at: The Sixth International Stockholm-Springfield Symposium of Advances in Alzheimer's Therapy; April 5-8, 2000; Stockholm, Sweden.
Cited by
Sorted by citations
Items 301–389 of 389
Shah, F. A., Qadir, H., Khan, J., & Faheem, M. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.03.064 · Cited by 3
OPTN protects retinal ganglion cells and ameliorates neuroinflammation in optic neuropathies
Wang, Q., Wang, Y., Jiang, Y., Donahue, R., Cao, G., Yan, W., Guo, H., Li, Z., Liang, J., Hao, J., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08534-6 · Cited by 3
Testai, F. D., & Gorelick, P. B. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-010-6_12 · Cited by 3
S3-Leitlinie »Demenzen« — Kurzversion
Maier, W., Jessen, F., Schneider, F. W., Deuschl, G., Spottke, A. E., & Reichmann, H. (2010) · Springer eBooks · doi:10.1007/978-3-642-13092-2_3 · Cited by 3
Vascular Pharmacotherapy and Dementia
Piguet, O., & Garner, B. (2010) · Current Vascular Pharmacology · doi:10.2174/157016110790226705 · Cited by 3
Recent Developments in Treating Alzheimer’s Disease
Žerovnik, E., & Kopitar‐Jerala, N. (2016) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000220 · Cited by 3
Testai, F. D., & Gorelick, P. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-29152-9_15 · Cited by 3
Repurposing for Alzheimer’s and Parkinson’s Diseases
Mucke, H. A. (2017) · CRC Press eBooks · doi:10.4324/9781315373669-2 · Cited by 3
Peng, K.-P., & Chang, K. (2026) · 童綜合醫學雜誌 · doi:10.4103/etmj.etmj-d-25-00028 · Cited by 2
The immunology behind inflammaging—causes, sources, and mechanisms
Sturmlechner, I., LeBrasseur, N. K., Weyand, C. M., & Goronzy, J. J. (2026) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2026.05.031 · Cited by 3
Wang, Q.-Q., Sun, Q.-Q., Guo, Y.-S., Yin, S., & Zhou, J. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00571-3 · Cited by 2
Micronutrients in the Prevention and Improvement of the Standard Therapy for Alzheimer’s Disease
Prasad, K. N. (2019) · CRC Press eBooks · doi:10.1201/9780429243462-9 · Cited by 2
Nedeljković, N. V., Bojović, D. N., Živanović, A. S., Mijajlović, M. Ž., & Nikolić, M. V. (2022) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416522500351 · Cited by 2
Autoregulation: mediators and renin–angiotensin system in diseases and treatments
Mansour, A. S. (2023) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-023-00482-4 · Cited by 2
Medications and Cognition in Older Adults
Caporaso, G. L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3106-0_7 · Cited by 2
Hausner, L., & Frölich, L. (2013) · Nervenheilkunde · doi:10.1055/s-0038-1633367 · Cited by 2
Current and future treatments of memory complaints and Alzheimer’s disease
Summers, W. K. (2011) · Therapy · doi:10.2217/thy.11.60 · Cited by 2
Emerging concept of ageing: Inflammageing
Goto, M. (2009) · Inflammation and Regeneration · doi:10.2492/inflammregen.29.249 · Cited by 2
The role of COX inhibitors in various physiological systems
Mitchell, T., & der Merwe, E. V. (2010) · Pharmacy management · Cited by 2
Boyd, T. D. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.1962 · Cited by 2
NEUROLOGIC DISEASE AND ANESTHESIA
Culley, D. J., Brooks, M., & Crosby, G. J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-05908-4.10026-0 · Cited by 2
Stress oxydant et maladie d’Alzheimer
Gilbert, T., Drai, J., & Bonnefoy, M. (2013) · Springer eBooks · doi:10.1007/978-2-8178-0443-9_10 · Cited by 2
Streit, W. J. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780199794591.003.0008 · Cited by 2
Medications and Cognition in Older Adults
Caporaso, G. L. (2019) · Clinical handbooks in neuropsychology · doi:10.1007/978-3-319-93497-6_10 · Cited by 1
Li, E., Zhang, P., & Feng, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1783786 · Cited by 1
Mundo, S. R. (2026) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2026.1888548 · Cited by 1
Psychiatric Disorders in Dementia
Vermeiren, Y., Dam, D. V., & Deyn, P. P. D. (2014) · Springer eBooks · doi:10.1007/978-3-642-40384-2_11 · Cited by 1
Multiple Sclerosis, Alzheimer’s Disease, and Inflammation: A Hypothetical View
Bynoe, M. S., & Viret, C. (2012) · Molecular and integrative toxicology · doi:10.1007/978-1-61779-812-2_9 · Cited by 1
Complement Component (3b/4b) Receptor 1 (CR1)
Lord, J., & Morgan, K. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7309-1_5 · Cited by 1
Pijn bij dementie: van experiment tot betere zorg
Achterberg, W. P., Universitair, L., & Scherder, E. (2010) · Cited by 1
Segărceanu, A., Prada, G. I., Ionescu, C., Arsene, A. L., Fulga, I., & Davila, C. (2012) · Cited by 1
Study Name, Authorship, Titling, and Credits
Meinert, C. L. (2020) · Springer eBooks · doi:10.1007/978-3-319-52677-5_187-1 · Cited by 1
S3-Leitlinie „Demenzen“: Symptomatische Therapie der Demenzen
Frölich, L. (2010) · Der Nervenarzt · Cited by 1
Linking heart function and analgesia
Saltelli, G., Paladini, A., Rekatsina, M., & Varrassi, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820589-1.00025-7 · Cited by 1
Lord, J., & Morgan, K. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7309-1_3 · Cited by 1
Neurologic Disease and Anesthesia
Du, A., Culley, D. J., & Crosby, G. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93273-8.00025-0 · Cited by 1
Médicaments et cognition chez le sujet âgé
Brefel‐Courbon, C. (2015) · Therapies · doi:10.2515/therapie/2015038 · Cited by 1
Alzheimer’s Disease: What Do We Know About It and How Can We Tackle It?
Mirpuri, B. (2022) · International journal of high school research · doi:10.36838/v4i2.13
Paliwal, A., Nigam, A. K., Gour, J. K., Singh, D., Pandey, P., & Singh, M. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819212-2.00018-9 · Cited by 1
Study Name, Authorship, Titling, and Credits
Meinert, C. L. (2022) · Springer eBooks · doi:10.1007/978-3-319-52636-2_187 · Cited by 1
Regulación de la plasticidad astrocitaria por ibuprofeno y FGF2
Lichtenstein, M. P. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
Pedrini, S., Morici, M., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch14 · Cited by 1
Jin, M., Xu, R., Wang, L., Alam, M. M., Ma, Z., Zhu, S., Martini, A. C., Jadali, A., Bernabucci, M., Xie, P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.22.473858 · Cited by 1
Hepburn, J. D. (2012) · Scholarship@Western (Western University)
NSAIDs and cardiovascular drugs in neurodegenerative and cerebrovascular diseases
Haag, M. D. M. (2009) · RePub (Erasmus University Rotterdam)
Intranasal insulin administration and declarative memory: A systematic review
Gualdrón, A. J., & Ávila, V. Á. (2008) · Revista de la Facultad de Medicina
Aradi, S. D. (2011) · Digital Commons - University of South Florida (University of South Florida)
Alzheimer's Disease: Risk Factors and Preventive Strategies
Tschanz, J. T., & Breitner, J. C. S. (2010) · doi:10.1002/9780470669600.ch47
Preserving the Memories: Managing Dementia
Seitz, D. P., Lee, P. E., Gill, S. S., & Rochon, P. A. (2010) · Wiley eBooks · doi:10.1002/9781118281796.ch7
Microglia demostrate age-dependent performance and interaction with beta-amyloid peptide
Lidónio, G. M. D. C., Brites, D. M. T. O., & Dias, D. M. A. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Gualdrón, A. J., & Ávila, V. Á. (2008) · Revista de la Facultad de Medicina
Rojas-Martinez, J. C. (2009) · Texas ScholarWorks (Texas Digital Library)
P2‐030: INVESTIGATING THE ROLE OF CLU, PICALM, AND CR1 IN ALZHEIMER'S DISEASE
Lord, J., Turton, J. C., Braae, A., Barber, I., Medway, C., Brown, K. S., & Morgan, K. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.703
Choi, Y.-S., -, J. E., Nam, S., & td, S. K. M. D. (2011) · Journal of the Korean Geriatrics Society · doi:10.4235/jkgs.2011.15.3.144
Resolution of inflammation in Alzheimer’s disease
Wang, X. (2014) · Figshare
Herpesvirus Infection and Immunity in Neurocognitive Disorders
Westman, G. (2015) · Uppsala University Publications (Uppsala University)
Guardia‐Laguarta, C. (2010) · TDX (Tesis Doctorals en Xarxa)
Kern, S., Skoog, N., Östling, S., Kern, J., & Börjesson-Hanson, N. (2012)
Using TUDCA to treat Alzheimer's disease after pathology onset in APP/PS1 mice
Dionísio, P. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Profiling cerebrospinal fluid proteins in Alzheimer's disease
Krishnamachari, S. R. (2011) · ThinkTech (Texas Tech University)
Drye, L. T., & Meinert, C. L. (2011) · Pharmaceutical Medicine · doi:10.1007/bf03256880
Using TUDCA to treat Alzheimer's disease after pathology onset in APP/PS1 mice
Farmácia, F. D. (2014)
DeCarlo, C. A. (2016) · UVic’s Research and Learning Repository (University of Victoria)
Daryani, S., Farzaei, A., Hosseinmardi, N., Bahrami, F., & Janahmadi, M. (2016)
Gate, D., & Town, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802851-3.00012-7
Wilson, J. H., Criss, A. H., Spangler, S. A., Walukevich‐Dienst, K., & Hewett, S. J. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117724406
Gao, H., Gao, Y., Tu, D., Liu, Y., Zhou, H., & Hong, J. (2017) · Wiley-VCH eBooks · doi:10.1002/9783527692156.ch48
da Silva, P. N., de Lima, R. K. S., & da Silva, C. P. (2020) · ID on line REVISTA DE PSICOLOGIA · doi:10.14295/idonline.v14i50.2516
Psychiatric Disorders in Dementia
Vermeiren, Y., Dam, D. V., de Vries, M., & Deyn, P. P. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-57231-0_9
Current awareness in geriatric psychiatry
(2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1918
Immune dysregulation and neurodegenerative diseases
Cipollini, V., Troili, F., & Giubilei, F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85841-0.00015-8
Hernández, T. D. R., Gore, S. V., Kreiling, J. A., & Créton, R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.12.557235
Combination therapies delay cognitive decline over 10 years in Alzheimer’s NACC participantsPreprint
Shang, Y., Torrandell‐Haro, G., Vitali, F., & Brinton, R. D. (2024) · medRxiv · doi:10.1101/2024.01.31.24301055
Alzheimer's Disease is Associated with Robust Neuroingflammation in the Hippocampus of WomenPreprint
Acosta‐Martínez, M., Carter, V., Nessim, A., Dhawan, J., Beach, T. G., Serrano, G. E., Sundermann, E. E., & Biegon, A. R. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4834013
Spatial pattern analysis of A Aβ-monomer model with inflammation processes for Alzheimer’s disease
Estavoyer, M., Torres, N., Blohm, J., Banerjee, M., & Pujo-Menjouet, L. (2025) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/2025022
Analysis and Control of Alzheimers Disease Models
Lakshmi, N. S. (2025) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres2124
McDowell, B., Marr, C., Holmes, C., Edwards, C. J., Cardwell, C., McHenry, M., Meenagh, G., & McGuinness, B. (2024) · Figshare · doi:10.6084/m9.figshare.26552719
McDowell, B., Marr, C., Holmes, C., Edwards, C. J., Cardwell, C., McHenry, M., Meenagh, G., & McGuinness, B. (2024) · Figshare · doi:10.6084/m9.figshare.26552722
Acetylcholine and Cholinergic Modulation of Immune Responses
Nizri, E., & Brenner, T. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0888-8_3
Vautheny, A. (2019) · theses.fr (ABES) · doi:10.70675/1812d71aze8d9z48d6z87d1z5a23a4e81953
Rochoy, M. (2019) · theses.fr (ABES) · doi:10.70675/4560bf49z9fd2z42a9z83e6zdd4b8e4e87ea
Clinical Indication of the Role of Inflammation in Alzheimer’s Disease
Kumar, A., Sarkar, N., Kundu, M., Singh, V., & Dasgupta, D. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010010
Chen, C., Cheng, J., Yang, M., Li, J., Tao, S., Wang, P., & Pan, H. (2026) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.70823
New treatments on the horizon for Alzheimer’s and other neurodegenerative diseases
Bailey, H., Layfield, R., & Žerovnik, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34176-2.00003-1
Zhao, X., Zeng, Y., Song, Z., He, J., He, Q., Lin, H., Liu, L., Yu, W., & Cheng, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209190
Tong, J., Li, L., Zhang, D., O’Brien, K. S., Lu, Y., Wu, Q., Zhou, T., Zhang, B., Lei, Y., Huilin, T., et al. (2026) · npj Health Systems · doi:10.1038/s44401-026-00160-6
Metadata
- Authors
- ADAPT Research Group*
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- ADAPT Research Group*
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2008-07-01
- Volume
- 65
- Issue
- 7
- Pages
- 896
- ISSN
- 0003-9942 (ISSN-L)
- PMC
- PMC2925195
- OpenAlex
- W1607135210
- Cited by
- 387
- References
- 20
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 9 · 2023: 8 · 2022: 19 · 2021: 15 · 2020: 18 · 2019: 15 · 2018: 9 · 2017: 18 · 2016: 24 · 2015: 25 · 2014: 29 · 2013: 18 · 2012: 34
- FWCI
- 28.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Eisai
- National Institute on Aging (U01AG015477, U01-AG15477)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- Alzheimer's disease, cognitive function, naproxen, celecoxib, nonsteroidal anti-inflammatory drugs, chemoprevention, dementia prevention, older adults, cognitive decline, ADAPT trial
- MeSH terms
- Celecoxib, Aged, Aged, 80 and over, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Cognition, Cognition Disorders, Double-Blind Method, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Naproxen, Pyrazoles, Sulfonamides, Time Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
